An assesor blind, balanced, randomized, two-treatment, two period, single-dose, two way crossover, comparative subcutaneous pharmacokinetic and pharmacodynamic study of two dose levels of INTP5 of Intas pharmaceuticals ltd., India Ahmedabad, India with two dose levels of Neulasta of Amgen (EU licensed product) in healthy, normal adult human subjects under fasting condition. - NA
Latest Information Update: 12 Aug 2019
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Intas Pharmaceuticals
- 31 Aug 2016 New trial record